Aprotinin 15,000 Kallikrein inactivator units/5ml solution vials
Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Aprotinin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Aprotinin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Clinical guidelines and formulary information
British National Formulary
Aprotinin
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
150 minutes
Mechanism
Aprotinin inhibits serine proteases including trypsin, chymotrypsin and plasmin…
Food interactions
None known
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100%
Half-life
150 minutes
Metabolism
Elimination
25-40%
After…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 385 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
After a 30 minute infusion of 1 million KIU, about 2% is excreted as unchanged drug.
After a larger dose of 2 million KIU infused over 30 minutes, urinary excretion of unchanged aprotinin accounts for approximately 9% of the dose.
Proteins and enzymes this drug interacts with in the body
PMID:6447255
Cleavage of fibronectin and laminin leads to cell detachment and apoptosis.
Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells
Enzymes involved in drug metabolism — important for understanding drug interactions
Involved compounds
ATC B02AB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Aprotinin
Additional database identifiers
Drugs Product Database (DPD)
11567
Drugs Product Database (DPD)
20461
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9475
GenAtlas
PRSS1
GeneCards
PRSS1
GenBank Gene Database
M22612
GenBank Protein Database
521216
Guide to Pharmacology
2397
UniProt Accession
TRY1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2521
GenAtlas
CTRB1
GeneCards
CTRB1
GenBank Gene Database
BC005385
Guide to Pharmacology
3272
UniProt Accession
CTRB1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9071
GenAtlas
PLG
GeneCards
PLG
GenBank Gene Database
X05199
GenBank Protein Database
387026
Guide to Pharmacology
2394
UniProt Accession
PLMN_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6357
GenAtlas
KLK1
GeneCards
KLK1
GenBank Gene Database
M25629
GenBank Protein Database
186653
Guide to Pharmacology
2865
UniProt Accession
KLK1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:983
GenAtlas
BCHE
GeneCards
BCHE
GenBank Gene Database
M32391
GenBank Protein Database
1311630
Guide to Pharmacology
2471
UniProt Accession
CHLE_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: